Literature DB >> 26467975

Retention in medication-assisted treatment for opiate dependence: A systematic review.

Christine Timko1,2, Nicole R Schultz3, Michael A Cucciare4,5,6, Lisa Vittorio7, Christina Garrison-Diehn1,2,8.   

Abstract

Retention in medication-assisted treatment among opiate-dependent patients is associated with better outcomes. This systematic review (55 articles, 2010-2014) found wide variability in retention rates (i.e., 19%-94% at 3-month, 46%-92% at 4-month, 3%-88% at 6-month, and 37%-91% at 12-month follow-ups in randomized controlled trials), and identified medication and behavioral therapy factors associated with retention. As expected, patients who received naltrexone or buprenorphine had better retention rates than patients who received a placebo or no medication. Consistent with prior research, methadone was associated with better retention than buprenorphine/naloxone. And, heroin-assisted treatment was associated with better retention than methadone among treatment-refractory patients. Only a single study examined retention in medication-assisted treatment for longer than 1 year, and studies of behavioral therapies may have lacked statistical power; thus, studies with longer-term follow-ups and larger samples are needed. Contingency management showed promise to increase retention, but other behavioral therapies to increase retention, such as supervision of medication consumption, or additional counseling, education, or support, failed to find differences between intervention and control conditions. Promising behavioral therapies to increase retention have yet to be identified.

Entities:  

Keywords:  Opiate dependence; behavioral therapies; medication-assisted treatment; systematic review; treatment retention

Mesh:

Substances:

Year:  2015        PMID: 26467975      PMCID: PMC6542472          DOI: 10.1080/10550887.2016.1100960

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  84 in total

1.  Evidence, hierarchies, and typologies: horses for courses.

Authors:  M Petticrew; H Roberts
Journal:  J Epidemiol Community Health       Date:  2003-07       Impact factor: 3.710

Review 2.  Drug addiction: the neurobiology of behaviour gone awry.

Authors:  Nora D Volkow; Ting-Kai Li
Journal:  Nat Rev Neurosci       Date:  2004-12       Impact factor: 34.870

3.  Controlled trial of prescribed heroin in the treatment of opioid addiction.

Authors:  Joan Carles March; Eugenia Oviedo-Joekes; Emilio Perea-Milla; Francisco Carrasco
Journal:  J Subst Abuse Treat       Date:  2006-07-18

4.  Predictors of program completion for women in residential substance abuse treatment.

Authors:  D K Knight; S M Logan; D D Simpson
Journal:  Am J Drug Alcohol Abuse       Date:  2001-02       Impact factor: 3.829

5.  A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals.

Authors:  Richard A Rawson; Michael J McCann; Frank Flammino; Steven Shoptaw; Karen Miotto; Chris Reiber; Walter Ling
Journal:  Addiction       Date:  2006-02       Impact factor: 6.526

6.  Evaluating long-term effects of heroin-assisted treatment: the results of a 6-year follow-up.

Authors:  Franziska Güttinger; Patrick Gschwend; Bernd Schulte; Jürgen Rehm; Ambros Uchtenhagen
Journal:  Eur Addict Res       Date:  2003-04       Impact factor: 3.015

Review 7.  Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

Authors:  Y Adi; A Juarez-Garcia; D Wang; S Jowett; E Frew; E Day; S Bayliss; T Roberts; A Burls
Journal:  Health Technol Assess       Date:  2007-02       Impact factor: 4.014

Review 8.  Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review.

Authors:  Björn Axel Johansson; Mats Berglund; Anna Lindgren
Journal:  Addiction       Date:  2006-04       Impact factor: 6.526

9.  Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials.

Authors:  Wim van den Brink; Vincent M Hendriks; Peter Blanken; Maarten W J Koeter; Barbara J van Zwieten; Jan M van Ree
Journal:  BMJ       Date:  2003-08-09

10.  Heroin-assisted treatment for opioid dependence: randomised controlled trial.

Authors:  Christian Haasen; Uwe Verthein; Peter Degkwitz; Juergen Berger; Michael Krausz; Dieter Naber
Journal:  Br J Psychiatry       Date:  2007-07       Impact factor: 9.319

View more
  115 in total

1.  Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.

Authors:  Melanie S Askari; Silvia S Martins; Pia M Mauro
Journal:  J Subst Abuse Treat       Date:  2020-05-11

2.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

3.  Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.

Authors:  Alisa B Busch; Shelly F Greenfield; Sharon Reif; Sharon-Lise T Normand; Haiden A Huskamp
Journal:  J Subst Abuse Treat       Date:  2020-05-22

4.  Trends in Abstinence and Retention Associated with a Medication-Assisted Treatment Program for People with Opioid Use Disorders.

Authors:  Kimberly D Brunisholz; Andrew J Knighton; Amulya Sharma; Lisa Nichols; Kristen Reisig; Jed Burton; Debbie Scovill; Carolyn Tometich; Mark Foote; Shelly Read; Scott Whittle
Journal:  Prog Community Health Partnersh       Date:  2020

5.  Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine.

Authors:  Julia Rozanova; Olga Morozova; Lyuba Azbel; Chethan Bachireddy; Jacob M Izenberg; Tetiana Kiriazova; Sergiy Dvoryak; Frederick L Altice
Journal:  J Urban Health       Date:  2018-08       Impact factor: 3.671

6.  Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.

Authors:  Amanda Sharp; Melissa Carlson; Veronica Howell; Kathleen Moore; Zev Schuman-Olivier
Journal:  J Subst Abuse Treat       Date:  2020-12-11

7.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

8.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

Review 9.  Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review.

Authors:  Simeon Kimmel; Paxton Bach; Alexander Y Walley
Journal:  J Gen Intern Med       Date:  2020-05-27       Impact factor: 5.128

10.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Authors:  Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner
Journal:  Addiction       Date:  2020-02-24       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.